Laboratory biomarkers associated with COVID-19 severity and management

Laboratory biomarkers associated with COVID-19 severity and management

Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 221(2020) vom: 01. Dez., Seite 108614
1. Verfasser: Keddie, S (VerfasserIn)
Weitere Verfasser: Ziff, O, Chou, M K L, Taylor, R L, Heslegrave, A, Garr, E, Lakdawala, N, Church, A, Ludwig, D, Manson, J, Scully, M, Nastouli, E, Chapman, M D, Hart, M, Lunn, M P
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Biomarkers COVID-19 CRP Cytokines IL-10 IL-6 Intensive care LDH mehr... IL10 protein, human IL6 protein, human Interleukin-6 Interleukin-10 130068-27-8 C-Reactive Protein 9007-41-4 L-Lactate Dehydrogenase EC 1.1.1.27
LEADER 01000caa a22002652c 4500
001 NLM317220993
003 DE-627
005 20250228080425.0
007 cr uuu---uuuuu
008 231225s2020 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2020.108614  |2 doi 
028 5 2 |a pubmed25n1057.xml 
035 |a (DE-627)NLM317220993 
035 |a (NLM)33153974 
035 |a (PII)S1521-6616(20)30774-9 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Keddie, S  |e verfasserin  |4 aut 
245 1 0 |a Laboratory biomarkers associated with COVID-19 severity and management 
264 1 |c 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 04.12.2020 
500 |a Date Revised 21.12.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved. 
520 |a The heterogeneous disease course of COVID-19 is unpredictable, ranging from mild self-limiting symptoms to cytokine storms, acute respiratory distress syndrome (ARDS), multi-organ failure and death. Identification of high-risk cases will enable appropriate intervention and escalation. This study investigates the routine laboratory tests and cytokines implicated in COVID-19 for their potential application as biomarkers of disease severity, respiratory failure and need of higher-level care. From analysis of 203 samples, CRP, IL-6, IL-10 and LDH were most strongly correlated with the WHO ordinal scale of illness severity, the fraction of inspired oxygen delivery, radiological evidence of ARDS and level of respiratory support (p ≤ 0.001). IL-6 levels of ≥3.27 pg/ml provide a sensitivity of 0.87 and specificity of 0.64 for a requirement of ventilation, and a CRP of ≥37 mg/l of 0.91 and 0.66. Reliable stratification of high-risk cases has significant implications on patient triage, resource management and potentially the initiation of novel therapies in severe patients 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Biomarkers 
650 4 |a COVID-19 
650 4 |a CRP 
650 4 |a Cytokines 
650 4 |a IL-10 
650 4 |a IL-6 
650 4 |a Intensive care 
650 4 |a LDH 
650 7 |a Biomarkers  |2 NLM 
650 7 |a IL10 protein, human  |2 NLM 
650 7 |a IL6 protein, human  |2 NLM 
650 7 |a Interleukin-6  |2 NLM 
650 7 |a Interleukin-10  |2 NLM 
650 7 |a 130068-27-8  |2 NLM 
650 7 |a C-Reactive Protein  |2 NLM 
650 7 |a 9007-41-4  |2 NLM 
650 7 |a L-Lactate Dehydrogenase  |2 NLM 
650 7 |a EC 1.1.1.27  |2 NLM 
700 1 |a Ziff, O  |e verfasserin  |4 aut 
700 1 |a Chou, M K L  |e verfasserin  |4 aut 
700 1 |a Taylor, R L  |e verfasserin  |4 aut 
700 1 |a Heslegrave, A  |e verfasserin  |4 aut 
700 1 |a Garr, E  |e verfasserin  |4 aut 
700 1 |a Lakdawala, N  |e verfasserin  |4 aut 
700 1 |a Church, A  |e verfasserin  |4 aut 
700 1 |a Ludwig, D  |e verfasserin  |4 aut 
700 1 |a Manson, J  |e verfasserin  |4 aut 
700 1 |a Scully, M  |e verfasserin  |4 aut 
700 1 |a Nastouli, E  |e verfasserin  |4 aut 
700 1 |a Chapman, M D  |e verfasserin  |4 aut 
700 1 |a Hart, M  |e verfasserin  |4 aut 
700 1 |a Lunn, M P  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 221(2020) vom: 01. Dez., Seite 108614  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:221  |g year:2020  |g day:01  |g month:12  |g pages:108614 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2020.108614  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 221  |j 2020  |b 01  |c 12  |h 108614